Remission in CML After 96 Weeks
Published: 2018-06-25 |
Author: Alexander M. Castellino, PhD |
Source: Cancer Therapy Advisor
A long-term follow-up of the ENEST freedom study reported that 96 weeks after stopping treatment, nearly half (48.9%) of patients with chronic myeloid leukemia (CML) with front-line treatment with nilotinib remained in treatment-free remission (TFR).
ENEST freedom was the first study specifically designed to assess the feasibility of TFR in patients with CML who achieved a DMR after front-line treatment with nilotinib. The physicians concluded their findings demonstrated the overall durability of TFR.
The primary analysis in 190 patients who entered the TFR phase of the study showed 51.6% of patients retained their major molecular response (MMR) at 48 weeks after stopping nilotinib; achieving TFR was a determining factor in nilotinib being named the first TKI to get the mention of long-term TFR in its product label.
The median duration of follow-up of the 96-week data cut-off was 75.9 weeks. At this time, 93 of the 190 patients (48.9%) remained in the TFR phase, 88 (46.3%) re-initiated nilotinib after loss of MMR, and 9 (4.7%) discontinued from the in the TFR phase.